Trial Profile

A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ravulizumab (Primary)
Indications Neuromyelitis optica
Focus Registrational; Therapeutic Use
Acronyms CHAMPION-NMOSD
Sponsors Alexion AstraZeneca Rare Disease

Most Recent Events

31 Dec 2024 Status changed from active, no longer recruiting to completed.
22 Oct 2024 Planned End Date changed from 31 Jul 2024 to 14 Feb 2025.
18 Apr 2024 Results assessing efficacy and safety of eculizumab and ravulizumab from PREVENT and CHAMPION-NMOSD trils presented at the 76th Annual Meeting of the American Academy of Neurology 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com